Skip to main content

Table 1 Baseline characteristics of patients according to treatment groups: clinical, immunovirological and body composition data, biological markers

From: Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study

Parameter

+ PI (n = 16)

+ NNRTI (n = 19)

p

Normal range

Age, y

42.3 (14.5)*

39.7 (11.9)*

0.57

 

Sex ratio (M,%)

62.5

63.2

0.96

 

Origin

  

0.96

 

  European (%)

75.0

73.7

  African (%)

25.0

26.3

Current smokers (%)

0

31.6

0.03

 

Duration of diagnosed infection, years

2.2 (2.9)*

1.6 (1.8)*

0.46

 

CDC categories

  

0.31

 

  A + B (%)

81.3

94.7

  C (%)

18.7

5.3

Viral load (log10/ml)

5.05 (0.85)*

5.04 (0.55)*

0.97

 

CD4 lymphocytes/ml

240 (153)*

240 (131)*

0.90

 

BMI, kg/m2

23.8 (3.6)*

24.0 (3.6)*

0.84

 

Body Lean Mass, kg

46.3 (8.8)*

49.4 (10.3)*

0.35

 

Body Fat Mass, kg

18.4 (8.9)*

19.4 (10.9)*

0.79

 

Fat Mass ratio

0.97

0.97

0.99

 

  In men

1.05 (0.16)*

1.03 (0.14)*

0.81

≤ 1.5

  In women

0.85 (0.10)*

0.87 (0.14)*

0.74

≤ 1.2

BMD L2-L4 (g/cm2)

1.233

1.249

0.82

 

Cholesterol, g/l

1.88 (0.45)*

1.61 (0.34)*

0.05

1.5 – 2.2

HDL-cholesterol, g/l

0.44 (0.08)*

0.38 (0.10)*

0.10

> 0.4

Triglycerides, g/l

1.14 (0.58)*

0.99 (0.48)*

0.46

0.5 – 1.5

Glucose, g/l

0.84 (0.08)*

0.83 (0.09)*

0.79

0.72 - .1.05

Total alkaline phosphatase, U/l

168 (37)*

173 (49)*

0.73

100 – 280

Bone alkaline phosphatase, μg/l

8.1 (3.2)*

8.3 (2.6)*

0.88

5 – 20

β-Cross-laps, μg/l

353 (186)*

302 (161)*

0.39

160 – 440

25-OH-vitamine D3, μg/l

20.7 (8.2)*

19.4 (12.0)*

0.71

22 – 45

1,25-di-OH-vitaminne D3, ng/l

49.1 (18.7)*

49.3 (18.4)*

0.97

25 – 60

Parathormone, ng/l

34.1 (12.9)*

35.1 (13.3)*

0.83

10 - 65

Cockroft (ml/min)

83.9 (21.9)*

102.3 (17.3)*

0.01

 
  1. * mean value (standard deviation).